Selective cell removal may tame stem cell Transplant's dangerous side effect
NCT ID NCT07660783
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether removing a specific type of immune cell (naive T cells) from a donor's stem cell graft can prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the recipient's body. The trial enrolls people with non-malignant blood disorders such as bone marrow failure, sickle cell disease, or immune deficiencies who need a stem cell transplant. Participants receive chemotherapy and low-dose radiation before the specially processed donor stem cells are infused.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD34-enriched, CD45RA-depleted donor stem cells
What this could lead to
If successful, this approach could reduce severe graft-versus-host disease after stem cell transplant for non-malignant blood disorders, improving safety and quality of life.
What could go wrong
This is a small, early-phase trial. The special graft may not prevent GVHD as hoped, and risks like infection or graft failure remain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOGLOBINOPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States